HEMATOLOGY

The FDA has granted a priority review to a supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) for use as a treatment for patients with refractory classical Hodgkin lymphoma.

Thomas E. Witzig, MD, hematologist-oncologist, Mayo Clinic, discusses some of the issues that still need to be addressed in diffuse large B-cell lymphoma.

The FDA has granted a full approval and label update to ponatinib (Iclusig) for patients with chronic phase (CP), accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

The European Commission has granted a conditional approval to ixazomib (Ninlaro) in combination with lenalidomide and dexamethasone for adult patients with multiple myeloma.

Robert A. Figlin, MD has been appointed the deputy director of the Integrated Oncology Service Line at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center.

Clinical trial findings from the past year will likely have a game-changing effect on the multiple myeloma landscape, according to Rafael Fonseca, MD.

The American Society of Hematology (ASH) has announced that it will honor the late David Grimwade, PhD, with the 2016 Exemplary Service Award.

Daratumumab (Darzalex) has received FDA approval in combination with lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.

The FDA has granted a priority review to the multikinase inhibitor midostaurin as a treatment for patients with newly-diagnosed&nbsp;<em>FLT3</em>-mutated acute myeloid leukemia or advanced systemic mastocytosis.

The FDA has granted a breakthrough therapy designation to the brentuximab vedotin for the treatment of patients with CD30-positive mycosis fungoides or primary cutaneous anaplastic large cell lymphoma following at least 1 prior systemic therapy.&nbsp;<br /> &nbsp;

When it comes to adverse events and duration of response, next-generation BTK inhibitors in chronic lymphocytic leukemia compare favorably with ibrutinib.

Immune checkpoint inhibitor development is progressing as treatments for patients with acute myeloid leukemia and myelodysplastic syndrome, with a number of studies currently assessing new combination strategies.

Studies testing immune checkpoint inhibitors in combination with other agents for the treatment of both Hodgkin and non-Hodgkin lymphoma are garnering attention among researchers.

Steven Coutre, MD,&nbsp;professor of medicine, Stanford University School of Medicine, discusses the benefits and drawbacks of the different frontline treatment options for&nbsp;chronic lymphocytic leukemia (CLL).

Alessandra Ferrajoli, MD,&nbsp;discusses the challenge with secondary malignancies in patients with CLL.

William G. Wierda, MD, PhD, discusses&nbsp;provided his expert insight on the frontline treatment of patients with CLL.

Updated data from the CheckMate-205 trial demonstrated that nivolumab (Opdivo) had an objective response rate (ORR) of 73% in a cohort of patients with classical Hodgkin lymphoma.

Chronic Lymphocytic Leukemia with Steven Coutre, MD

Chronic Lymphocytic Leukemia with Steven Coutre, MD